TLC gains US/EU orphan status for liver cancer drug
This article was originally published in Scrip
Executive Summary
The Taiwanese drug delivery firm Taiwan Liposome Company (TLC) has been granted orphan status in both the US and EU for its pipeline oncology product Lipotecan (TLC388), for the treatment of hepatocellular carcinoma (HCC).